PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24329500-5	2014	Hepatic clearance of docetaxel was enhanced in vitro and in vivo at dosage of 120 and 180 mg kg(-1), and CYP3A activity was up-regulated by measuring the formation rate of 1-hydroxymidazolam.	Docetaxel	21-30	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	105-110	
28716728-6	2017	The results showed that docetaxel not only inhibited the CYP3A-mediated biotransformation of erlotinib in vitro, but also significantly increased the maximum concentration and systemic exposure of erlotinib in vivo in WT rats.	Docetaxel	24-33	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	57-62	
28716728-9	2017	These results exhibited the potentials of erlotinib-docetaxel interaction and indicated that the CYP3A played the perpetrating role of docetaxel on erlotinib in rats.	Docetaxel	52-61	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	97-102	
28716728-9	2017	These results exhibited the potentials of erlotinib-docetaxel interaction and indicated that the CYP3A played the perpetrating role of docetaxel on erlotinib in rats.	Docetaxel	135-144	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	97-102	
22936118-7	2012	Thus the pharmacokinetic changes of taxanes observed in the DMIS rats were attributed to changes in P-gp and Cyp3A, predominant factors that control the absorption of paclitaxel and docetaxel, respectively.	Docetaxel	182-191	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	109-114	
11561777-0	2001	Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel.	Docetaxel	87-96	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	22-27	
11561777-4	2001	Recently, paclitaxel, a compound structurally related to docetaxel, has been shown to significantly elevate the expression of CYP3A in rat and human hepatocytes.	Docetaxel	57-66	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	126-131	
22201019-7	2012	Thus, the enhanced bioavailability of oral docetaxel by curcumin SEDDS seemed to be likely due to an inhibition function of cytochrome P450 (CYP) 3A and P-glycoprotein (Pgp) in the intestines of the rats.	Docetaxel	43-52	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	124-148	
22067009-4	2012	The AUCs (the areas under the plasma concentration-time curve from time zero to time infinity) of intravenous docetaxel in PCM rats were significantly greater than in the control rats because of the significant decrease in the hepatic CYP3A.	Docetaxel	110-119	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	235-240	
20727390-1	2010	As with many other anti-cancer agents, docetaxel is a substrate for ATP-binding cassette transporters such as P-glycoprotein and its metabolism is mainly catalysed by CYP3A.	Docetaxel	39-48	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	167-172	
20727390-2	2010	In order to improve the oral bioavailability of docetaxel, a component of turmeric, curcumin, which can down-regulate the intestinal P-glycoprotein and CYP3A protein levels, was used for the pre-treatment of rats before the oral administration of docetaxel.	Docetaxel	48-57	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	152-157	
20663044-7	2010	CONCLUSIONS: The inhibition for the metabolism of docetaxel via hepatic and intestinal CYP3A subfamily, and inhibition of P-glycoprotein-mediated efflux of docetaxel in the intestine by tesmilifene were almost negligible.	Docetaxel	50-59	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	87-92	
11561777-9	2001	RESULTS: We observed that by day 3 of drug treatment, docetaxel at concentration in the range of 2.5-10 microM increased the CYP3A enzymatic activity and the immunoreactive CYP3A levels in a concentration-dependent manner.	Docetaxel	54-63	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	125-130	
11561777-9	2001	RESULTS: We observed that by day 3 of drug treatment, docetaxel at concentration in the range of 2.5-10 microM increased the CYP3A enzymatic activity and the immunoreactive CYP3A levels in a concentration-dependent manner.	Docetaxel	54-63	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	173-178	
11561777-10	2001	At the 10 microM level, docetaxel caused a twofold increase in the CYP3A activity and a threefold increase in the immunoreactive CYP3A levels.	Docetaxel	24-33	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	67-72	
11561777-10	2001	At the 10 microM level, docetaxel caused a twofold increase in the CYP3A activity and a threefold increase in the immunoreactive CYP3A levels.	Docetaxel	24-33	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	129-134	
11561777-11	2001	However, the docetaxel-mediated CYP3A activity and enzyme level increase were significantly lower than those mediated by paclitaxel and dexamethasone.	Docetaxel	13-22	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	32-37	
11561777-13	2001	CONCLUSIONS: Taken together, our findings raise the possibility that docetaxel at clinically relevant concentrations increases CYP3A activity.	Docetaxel	69-78	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	127-132